Research ExplorerPublicationsHigh Incidence of De Novo and Subclinical Atrial Fibrillatio...

High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device

Standard

High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. / Wilke, Iris; Witzel, Katrin; Münch, Julia; Pecha, Simon; Blankenberg, Stephan; Reichenspurner, Hermann; Willems, Stephan; Patten, Monica; Aydin, Ali.

In: J CARDIOVASC ELECTR, Vol. 27, No. 7, 07.2016, p. 779-784.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wilke, I, Witzel, K, Münch, J, Pecha, S, Blankenberg, S, Reichenspurner, H, Willems, S, Patten, M & Aydin, A 2016, 'High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device', J CARDIOVASC ELECTR, vol. 27, no. 7, pp. 779-784. https://doi.org/10.1111/jce.12982

APA

Wilke, I., Witzel, K., Münch, J., Pecha, S., Blankenberg, S., Reichenspurner, H., Willems, S., Patten, M., & Aydin, A. (2016). High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J CARDIOVASC ELECTR, 27(7), 779-784. https://doi.org/10.1111/jce.12982

Vancouver

Wilke I, Witzel K, Münch J, Pecha S, Blankenberg S, Reichenspurner H et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J CARDIOVASC ELECTR. 2016 Jul;27(7):779-784. https://doi.org/10.1111/jce.12982

Bibtex

@article{efc7c16dc61d4b098e9d6232932e50aa,
title = "High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device",
abstract = "INTRODUCTION: Atrial fibrillation (AF) is an important prognostic parameter in patients with hypertrophic cardiomyopathy (HCM). Though cardiac rhythm management (CRM) devices (e.g., ICD, pacemaker or implantable loop recorder) can detect subclinical AF, data describing the incidence of AF are rare. We therefore investigated the incidence and clinical impact of de novo and subclinical AF detected by CRM devices in patients with HCM.METHODS AND RESULTS: In our retrospective single-center study, we included patients with HCM and need for CRM devices. The primary endpoint of the study was the incidence of clinical and subclinical de novo AF. During follow-up, patients were screened for adverse events like stroke, ventricular arrhythmia, heart failure, or death. From 192 HCM patients, 44 patients received a CRM device (38 ICDs, 5 pacemakers, 1 implantable loop recorder). In 14 of these patients (32%), AF had been documented before device implantation. Thirty (68%) patients were free from AF at the time of implantation. During a median follow-up of 595 days (interquartile range, 367-890 days), de novo AF was recorded in 16 of these 30 patients (53%). Fourteen (88%) of the 16 patients with de novo AF were free from any clinical symptoms, so these patients were classified to have subclinical AF. In logistic regression analysis, age was the only significant predictor for an increased risk of AF.CONCLUSION: AF is common in patients with HCM who need a CRM device. More than 50% of these patients develop de novo AF that was predominantly subclinical in our cohort.",
keywords = "Adult, Age Factors, Aged, Asymptomatic Diseases, Atrial Fibrillation/diagnosis, Cardiac Pacing, Artificial, Cardiomyopathy, Hypertrophic/diagnosis, Defibrillators, Implantable, Electric Countershock/instrumentation, Female, Germany/epidemiology, Humans, Incidence, Logistic Models, Male, Middle Aged, Pacemaker, Artificial, Retrospective Studies, Risk Factors, Treatment Outcome",
author = "Iris Wilke and Katrin Witzel and Julia M{\"u}nch and Simon Pecha and Stephan Blankenberg and Hermann Reichenspurner and Stephan Willems and Monica Patten and Ali Aydin",
note = "{\textcopyright} 2016 Wiley Periodicals, Inc.",
year = "2016",
month = jul,
doi = "10.1111/jce.12982",
language = "English",
volume = "27",
pages = "779--784",
journal = "J CARDIOVASC ELECTR",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device

AU - Wilke, Iris

AU - Witzel, Katrin

AU - Münch, Julia

AU - Pecha, Simon

AU - Blankenberg, Stephan

AU - Reichenspurner, Hermann

AU - Willems, Stephan

AU - Patten, Monica

AU - Aydin, Ali

N1 - © 2016 Wiley Periodicals, Inc.

PY - 2016/7

Y1 - 2016/7

N2 - INTRODUCTION: Atrial fibrillation (AF) is an important prognostic parameter in patients with hypertrophic cardiomyopathy (HCM). Though cardiac rhythm management (CRM) devices (e.g., ICD, pacemaker or implantable loop recorder) can detect subclinical AF, data describing the incidence of AF are rare. We therefore investigated the incidence and clinical impact of de novo and subclinical AF detected by CRM devices in patients with HCM.METHODS AND RESULTS: In our retrospective single-center study, we included patients with HCM and need for CRM devices. The primary endpoint of the study was the incidence of clinical and subclinical de novo AF. During follow-up, patients were screened for adverse events like stroke, ventricular arrhythmia, heart failure, or death. From 192 HCM patients, 44 patients received a CRM device (38 ICDs, 5 pacemakers, 1 implantable loop recorder). In 14 of these patients (32%), AF had been documented before device implantation. Thirty (68%) patients were free from AF at the time of implantation. During a median follow-up of 595 days (interquartile range, 367-890 days), de novo AF was recorded in 16 of these 30 patients (53%). Fourteen (88%) of the 16 patients with de novo AF were free from any clinical symptoms, so these patients were classified to have subclinical AF. In logistic regression analysis, age was the only significant predictor for an increased risk of AF.CONCLUSION: AF is common in patients with HCM who need a CRM device. More than 50% of these patients develop de novo AF that was predominantly subclinical in our cohort.

AB - INTRODUCTION: Atrial fibrillation (AF) is an important prognostic parameter in patients with hypertrophic cardiomyopathy (HCM). Though cardiac rhythm management (CRM) devices (e.g., ICD, pacemaker or implantable loop recorder) can detect subclinical AF, data describing the incidence of AF are rare. We therefore investigated the incidence and clinical impact of de novo and subclinical AF detected by CRM devices in patients with HCM.METHODS AND RESULTS: In our retrospective single-center study, we included patients with HCM and need for CRM devices. The primary endpoint of the study was the incidence of clinical and subclinical de novo AF. During follow-up, patients were screened for adverse events like stroke, ventricular arrhythmia, heart failure, or death. From 192 HCM patients, 44 patients received a CRM device (38 ICDs, 5 pacemakers, 1 implantable loop recorder). In 14 of these patients (32%), AF had been documented before device implantation. Thirty (68%) patients were free from AF at the time of implantation. During a median follow-up of 595 days (interquartile range, 367-890 days), de novo AF was recorded in 16 of these 30 patients (53%). Fourteen (88%) of the 16 patients with de novo AF were free from any clinical symptoms, so these patients were classified to have subclinical AF. In logistic regression analysis, age was the only significant predictor for an increased risk of AF.CONCLUSION: AF is common in patients with HCM who need a CRM device. More than 50% of these patients develop de novo AF that was predominantly subclinical in our cohort.

KW - Adult

KW - Age Factors

KW - Aged

KW - Asymptomatic Diseases

KW - Atrial Fibrillation/diagnosis

KW - Cardiac Pacing, Artificial

KW - Cardiomyopathy, Hypertrophic/diagnosis

KW - Defibrillators, Implantable

KW - Electric Countershock/instrumentation

KW - Female

KW - Germany/epidemiology

KW - Humans

KW - Incidence

KW - Logistic Models

KW - Male

KW - Middle Aged

KW - Pacemaker, Artificial

KW - Retrospective Studies

KW - Risk Factors

KW - Treatment Outcome

U2 - 10.1111/jce.12982

DO - 10.1111/jce.12982

M3 - SCORING: Journal article

C2 - 27060297

VL - 27

SP - 779

EP - 784

JO - J CARDIOVASC ELECTR

JF - J CARDIOVASC ELECTR

SN - 1045-3873

IS - 7

ER -